VIP treatment has been evidenced to reduce bone erosion in the collagen-induced mouse model of arthritis (CIA) by modulating the synthesis of several osteoclastogenic factors as well as by lowering the RANKL/OPG ratio [36,37]. Here, TNFSF11 is linked to Arthritis.